Skip to content

Philip D Mosier

Department of Medicinal Chemistry and Institute for Structural Biology and Drug Discovery, Virginia Commonwealth University, Richmond, VA 23298-0540, USA.

4 papers in the library · 240 citations · publishing 2005-2014

Papers

Identification of the molecular mechanisms by which the diterpenoid salvinorin A binds to kappa-opioid receptors.

Biochemistry June 21, 2005 Feng Yan, Philip D Mosier, Richard B Westkaemper et al. 91 citations

Salvinorin A, a hallucinogenic compound from the plant Salvia divinorum, selectively and potently activates kappa-opioid receptors (KORs), making it the only known lipid-like molecule to do so and the only non-nitrogenous opioid receptor agonist. Key residues in KORs responsible for its high binding affinity and agonist efficacy were identified: interactions with tyrosine residues in helix 7 (Tyr313 and Tyr320) and helix 2 (Tyr119) stabilize salvinorin A in the binding pocket, while activation requires interactions with helix 7 tyrosines Tyr312, Tyr313, and Tyr320 and with Tyr139 in helix 3.

Structure-based design, synthesis, and biochemical and pharmacological characterization of novel salvinorin A analogues as active state probes of the kappa-opioid receptor.

Biochemistry July 28, 2009 Feng Yan, Ruslan V Bikbulatov, Viorel Mocanu et al. 81 citations

Salvinorin A, the most potent naturally occurring hallucinogen, targets the kappa-opioid receptor (KOR). Researchers designed and synthesized novel irreversible salvinorin A-derived ligands, RB-64 and RB-48, as active state probes of KOR. Based on molecular modeling, they targeted cysteine residue C315(7.38) for covalent binding. Both compounds were extraordinarily potent and selective KOR agonists in vitro and in vivo. RB-64 showed wash-resistant inhibition of binding requiring a free cysteine near the binding pocket. Mass spectrometry confirmed C315(7.38) as the anchoring residue and suggested a biochemical mechanism for covalent binding. These findings provide direct evidence of a free cysteine in the agonist-bound KOR state and insights into salvinorin A's binding and activation mechanism.

Differential helical orientations among related G protein-coupled receptors provide a novel mechanism for selectivity. Studies with salvinorin A and the kappa-opioid receptor.

The Journal of biological chemistry February 2, 2007 Timothy A Vortherms, Philip D Mosier, Richard B Westkaemper et al. 40 citations

Salvinorin A, the active compound in the hallucinogenic plant Salvia divinorum, binds selectively and potently to the kappa-opioid receptor (KOR). Unlike most ligands for peptide-binding receptors, it is non-nitrogenous and lipid-like. Using chimeric receptors, mutagenesis, accessibility methods, and modeling, the study found that helix 2 of KOR is essential for binding, with two valine residues (Val-108 and Val-118) conferring selectivity. Modeling suggested these residues indirectly affect binding by rotating helix 2. Accessibility experiments comparing KOR and the delta-opioid receptor, which does not bind salvinorin A, showed differential water accessibility of key residues, indicating that differences in helix 2 orientation are critical for salvinorin A's selective binding to KOR.

Michael acceptor approach to the design of new salvinorin A-based high affinity ligands for the kappa-opioid receptor.

European journal of medicinal chemistry October 6, 2014 Prabhakar R Polepally, Krzysztof Huben, Eyal Vardy et al. 28 citations

Salvinorin A, a compound from the plant Salvia divinorum, binds strongly and selectively to the κ-opioid receptor (KOR). A new series of salvinorin A derivatives with reactive Michael acceptor groups at C-2 was created to explore how the compound interacts with the receptor. Most of these derivatives retained high affinity for KOR, and some also bound to the μ-opioid receptor (MOR). None showed wash-resistant irreversible binding. Using the KOR crystal structure, mutagenesis data, and other methods, the researchers identified possible ways the new compounds interact with both KOR and MOR.